
Drug Repositioning in Glioblastoma: A Pathway Perspective
Glioblastoma multiforme (GBM) is the most malignant primary adult brain tumor. The current standard of care is surgical resection, radiation, and chemotherapy treatment, which extends life in most cases. Unfortunately, tumor recurrence is nearly universal and patients with recurrent glioblastoma typically survive less than one year. Read more “Drug Repositioning in Glioblastoma: A Pathway Perspective”